U.S. Healthcare Services Stock News

With inflation, energy shocks and shifting rate expectations shaping markets, many investors are looking beyond large caps and toward smaller, financially solid opportunities. The Financially Fit Penny Stocks screener focuses on companies trading below 5 that still aim for healthier balance sheets than the typical early stage stock, which can help reduce some of the risk that usually comes with low share prices. In this article, you will see 3 of the stocks from this screener, showing how...

Monarch Casino & Resort (MCRI) has put up another solid quarter, with Q2 2026 revenue of US$142.6 million and basic EPS of US$1.82, while trailing twelve month EPS sits at US$6.37 on revenue of US$562.0 million. The company has seen quarterly revenue move between US$125.4 million and US$142.8 million since early 2025, with basic EPS ranging from US$1.08 to US$1.82 over the same stretch. This sets up a story where earnings growth of 45.7% and a net profit margin of 20.4% over the past year...

Wave Life Sciences (WVE) has attracted investor attention after recent share price swings, with the stock closing at US$5.79. The move comes against a backdrop of mixed short term and longer term returns. See our latest analysis for Wave Life Sciences. Recent trading puts Wave Life Sciences on a weak near term trend, with the 7 day share price return down 5.55% and the 90 day share price return down 21.54%. However, the 3 year total shareholder return of 48.08% shows a much stronger longer...

Tariffs on imported generic drugs of up to 200% from 2029 could reshape where and how the medicines in US pharmacies are made, and that has real implications for US-based generic drug stocks. With 90% of US prescriptions filled by generics and about 70% of those sourced from overseas, investors are right to pay attention as policy pressure builds for more domestic manufacturing. This article looks at how that policy shock could affect US-based generic manufacturers and highlights three stocks...

Expro stock has delivered a strong 88.2% return over the past year, yet the current valuation checks point to a company that screens as expensive rather than a clear bargain. The 88.2% one year gain puts Expro firmly in the spotlight and raises the question of how much of the good news is already reflected in the share price. Expectations around Expro's ability to convert its project pipeline into steady cash flows can support the current valuation. However, any setback in execution or...

Acquisition news puts Adecoagro in focus Adecoagro (AGRO) has agreed to acquire the Caarapó Mill in Mato Grosso do Sul from Raízen Group. The move is planned to expand its Sugar, Ethanol and Energy segment, pending regulatory approval before October 1, 2026. See our latest analysis for Adecoagro. The acquisition agreement comes after a mixed year for Adecoagro’s stock, with the share price at US$10.78, a 30 day share price return of 16.67% but a 90 day share price return that fell 20.74%,...

GLOBALFOUNDRIES (GFS) stock is in focus after SEALSQ Corp. signed a Memorandum of Understanding with the company to co-develop secure semiconductor platforms and quantum-focused technologies, including Post Quantum Cryptography and cryoelectronic ASICs. See our latest analysis for GLOBALFOUNDRIES. Against this backdrop, GLOBALFOUNDRIES’ recent collaboration sits alongside a mixed price picture, with a 1-day share price return of 4.54% and a year-to-date share price return of 61.08%. The...

With inflation pressures tied to energy markets, shifting interest rate expectations across regions, and higher geopolitical risk, many investors are looking for sectors backed by long-term government demand and strong balance sheets. That is where the Financially Strong Drone Defense Stocks screener can help. It filters for companies with solid cash positions and low reliance on expensive borrowing, which can matter when funding heavy R&D and waiting for large contract payments. This article...

OFG Bancorp (OFG) has put up another solid set of numbers for Q2 2026, with total revenue of US$177.3 million and basic EPS of US$1.39, backed by trailing twelve month revenue of US$651.2 million and EPS of US$5.09 that sit against a 13.2% earnings growth rate over the past year. Over the last few quarters, revenue has moved from US$160.7 million in Q2 2025 to US$152.4 million in Q4 2025, US$163.5 million in Q1 2026 and now US$177.3 million in Q2 2026. Quarterly EPS has tracked from US$1.15...

Medline stock has gained 8.8% over the past month, and while the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside, the broader valuation checks paint a more mixed picture rather than a clear bargain. An 8.8% return over the past month suggests sentiment around Medline has turned more positive in the short term. The planned 1,000,000 square foot distribution facility in Perris, California can support expectations for future cash flow, but the capital intensity...

Horace Mann Educators Corporation recently held a Special Call, signaling that management had corporate updates or material information to share with investors and other stakeholders. Because Special Calls often accompany meaningful corporate developments, this event has drawn attention to how any new disclosures might affect Horace Mann’s long-term positioning with its educator-focused insurance and retirement offerings. With Horace Mann’s recent Special Call now completed, we’ll explore...

Southern First Bancshares (SFST) reported Q2 2026 total revenue of US$34.9 million and basic EPS of US$1.22, with trailing 12 month revenue at US$128.8 million and EPS at US$4.73, alongside trailing year earnings growth of 81.2%. Over recent quarters, the company has seen quarterly revenue move from US$27.9 million and EPS of US$0.81 in Q2 2025 to US$34.9 million and EPS of US$1.22 in Q2 2026. At the same time, trailing 12 month revenue shifted from US$102.9 million and EPS of US$2.71 to...

MakeMyTrip Limited recently disclosed that its wholly owned subsidiary, MakeMyTrip (India) Limited, had previously confidentially submitted a pre-filed draft red herring prospectus to Indian regulators for an IPO and listing on the Mumbai stock exchange, involving a sale of shares by MakeMyTrip and its Singapore-based unit ibibo Group Holdings. This planned India listing is intended to raise the profile of the MakeMyTrip brand locally and strengthen the company’s ability to attract and...

TechnipFMC's share price has very large 5 year returns behind it and now sits at US$74.62. A Discounted Cash Flow (DCF) intrinsic value estimate points to roughly 30.7% upside, while market multiples lean the other way and the broader value checks flag the stock as far from a clear bargain. Over 5 years, TechnipFMC has delivered very large total returns. This puts extra focus on whether the current price is still supported by fundamentals. Future project execution and cash flow visibility...

With inflation worries, higher energy costs, and central banks talking about keeping rates elevated, investors are paying closer attention to companies that already turn AI spending into real profits. That is exactly what the Profitable AI Stocks screener focuses on, highlighting businesses that are not just investing heavily in AI projects but are also generating cash from them. Instead of trying to guess which early stage ideas might work, you can study stocks that already show earnings...

Mobileye Global (NasdaqGS:MBLY) agreed to supply Stellantis with cloud-enhanced advanced driver-assistance systems starting in 2027. The partnership focuses on software-driven, connected safety features that rely on data and updates from the cloud. The deal expands Mobileye's role as a core technology provider to large global automakers. Mobileye Global, which trades at $8.99, is drawing fresh attention with its new agreement to power Stellantis vehicles with cloud-based driver-assistance...

Ionis Pharmaceuticals and AstraZeneca recently reported that the large Phase 3 CARDIO-TTRansform trial of eplontersen in ATTR cardiomyopathy did not meet its primary cardiovascular endpoint, while Ionis separately dosed the first child in its Phase 1-2 ASCEND trial of ION337 for Dravet syndrome, a rare and severe epileptic encephalopathy. This mix of a high-profile late-stage setback and early-stage progress in an underserved rare disease highlights both the uncertainty and breadth of Ionis’...

Earlier this week, Muddy Waters Research founder Carson Block accused SoFi Technologies of using fair value accounting on its loans in a way he described as a legal gray area, while SoFi responded that its practices comply with U.S. GAAP and SEC requirements. The clash has sharpened investor focus on how SoFi values and finances its loan book, an area central to understanding its business quality and risk profile. Next, we’ll examine how these fair value accounting concerns could affect...

Polestar Automotive Holding UK (PSNY) has drawn fresh attention after reporting first half 2026 retail sales volumes of 30,423 cars and announcing plans to open Finland's largest Polestar showroom with Wetteri in Helsinki. See our latest analysis for Polestar Automotive Holding UK. Despite the showroom expansion and steady first half volumes, Polestar Automotive Holding UK's share price has come under pressure, with the stock down 25.36% on a 1 month share price return basis and the 1 year...

Strategy stock has fallen sharply over the past year, yet on current checks it still screens as undervalued, with both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples pointing to a discount versus where the models place it. Over the past 3 years, Strategy has returned about 133.4%, which keeps the long term picture in positive territory despite recent volatility. The company’s concentrated Bitcoin treasury approach can support perceptions of upside if adoption...

Profitability Concerns Put Robert Half Stock in Focus Fresh commentary on shrinking profit margins at Robert Half (RHI), including falling earnings per share alongside revenue growth, has refocused attention on how these profitability pressures may be influencing current sentiment around the stock. See our latest analysis for Robert Half. Despite the pressure on margins, Robert Half’s share price has moved sharply, with a 7 day share price return of 15.46% and a year to date share price...

Astera Labs (ALAB) is back in focus after expanding its Taurus family of 3.2T Ethernet Smart Retimers and Smart Redrivers, a move aimed at hyperscalers and AI system providers seeking denser, more power efficient clusters. See our latest analysis for Astera Labs. Against the backdrop of this product expansion, Astera Labs’ recent share price action has been choppy, with a 1-day share price return of 3.46% at a latest share price of $319.79, a 30-day share price return down 23.32%, a 90-day...

Eton Pharmaceuticals (ETON) drew fresh attention after its stock climbed 13.8% on strong trading volume, with interest centering on its commercial rare disease portfolio and late-stage candidates such as Amglidia and the Zeneo hydrocortisone autoinjector. See our latest analysis for Eton Pharmaceuticals. That surge in Eton Pharmaceuticals’ share price fits into a much stronger run, with a 30 day share price return of 33% and year to date share price return of 165.68%. The 1 year total...

Lam Research (LRCX) is back in focus after management raised its 2026 wafer fabrication equipment outlook, citing AI driven demand for deposition and etch tools and a sector wide semiconductor rebound. See our latest analysis for Lam Research. The share price reaction has been choppy, with a 4.97% 1-day share price gain coming after a 7-day share price return of down 6.96% and a 30-day share price return of down 17.23%. However, the year-to-date share price return of 74% and a 1-year total...